REPLY: LEA Reply™ Reinforces its Supply Chain Resilience with AWS Foundational Technical Review Achievement
Logistics Reply, the Reply Group company specializing in innovative supply chain solutions, is pleased to announce that LEA Reply™, its modular and cloud-native platform for supply chain execution, has successfully completed the AWS Foundational Technical Review (FTR). Reinforcing its alignment with Amazon Web Services (AWS) best practices; LEA Reply™ continues to deliver on its commitment to providing secure, scalable, and forward-thinking solutions tailored to the evolving needs of the logistics and supply chain sectors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241217640641/en/
LEA Reply™ (Logistics Execution Architecture) is the latest evolution of logistics software: a digital platform for efficient, agile and connected supply chains. A suite of business microservices for inventory, warehousing, distribution, delivery, point-of-sales activities and end-to-end visibility. (Graphic: Business Wire)
The AWS Foundational Technical Review, based on the AWS Well-Architected Framework, reflects a comprehensive review of LEA Reply’s architecture. By meeting AWS’s stringent standards in security, reliability, performance, and operational excellence, Logistics Reply ensures that its platform is built to help customers tackle the complex challenges of modern supply chains. This validation also highlights the platform’s ability to integrate AWS’s capabilities to empower businesses with cutting-edge tools for scalability, data protection, and efficiency.
“The AWS Foundational Technical Review certification is a testament to our commitment to innovation, security, and reliability. said Enrico Nebuloni, Executive Partner at Reply. In a time when cybersecurity is a critical concern, this recognition reassures our customers that LEA Reply™ meets the highest standards of security, scalability, and operational resilience. By leveraging AWS infrastructure and adhering to its best practices, we provide a robust, cloud-native platform designed to handle the complexities of modern supply chains. This milestone strengthens our position as a trusted partner, enabling businesses to mitigate risks, enhance performance, and ensure business continuity with confidence.”
The AWS FTR Validation underscores LEA Reply’s capacity to address core challenges faced by supply chain professionals today:
- Resilience: Enhanced security measures protect critical operations and data.
- Agility: Scalable solutions that adapt to business growth and market shifts.
- Efficiency: Optimized performance through adherence to proven architectural frameworks.
- Cost-Effectiveness: Smart cloud resource management ensures value for investment.
By embedding AWS best practices into its DNA, Logistics Reply continues to deliver innovation that empowers supply chain leaders to navigate disruption, seize opportunities, and maintain a competitive edge.
To learn more about LEA Reply™ and its innovative supply chain solutions, visit www.lea-reply.com.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Logistics Reply
Logistics Reply is the Reply group company specialized in delivering state-of-the-art software to transform supply chains, blending modularity with enhanced connectivity, to meet the dynamic demands of modern warehousing and logistics. Our solutions ensure seamless collaboration between systems, humans and machines, creating a digital footprint orchestrating advanced automation. We optimize warehouse efficiency through smart robotics and enhance operational decision-making with AI. With over 25 years of pioneering experience, we lead clients through their digital transformation, ensuring rapid value and lasting quality. Discover our innovative software solutions at www.lea-reply.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241217640641/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press release
The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-dateIncome before income taxes of $5.1 million for the quarter and $13.2 million year-to-dateBacklog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income at
LambdaTest Unveils Next-Generation SmartUI Experience for Visual Testing23.12.2024 17:00:00 CET | Press release
LambdaTest unveils its redesigned SmartUI experience, transforming visual testing with seamless navigation, precise controls, and enhanced workflows. LambdaTest, a leading cloud-based unified testing platform has announced the general availability of its reimagined SmartUI screenshot page. This new update is all set to transform visual testing workflows, delivering a seamless, intuitive, and powerful experience tailored to the needs of testers and developers worldwide. The redesigned SmartUI interface introduces groundbreaking enhancements that prioritize user efficiency and precision. From the new pinch-to-zoom functionality for precise screenshot inspection to a streamlined navigation system featuring a side drawer for quick browsing, every detail has been thoughtfully crafted to improve productivity. The refreshed design also offers a cleaner, more spacious layout, ensuring that users can focus on what matters most—their screenshots. Smarter workflows now empower users with an intui
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases23.12.2024 13:00:00 CET | Press release
Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Chairman, President and Group CEO: Shigekazu Takeuchi; Head Office: Minato-ku, Tokyo), and Eisai Co., Ltd. (Representative Corporate Officer and CEO: Haruo Naito; Head Office: Bunkyo-ku, Tokyo; hereinafter "Eisai") announced today that they have entered into a memorandum of understanding for the joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases. Fujirebio and Eisai have been conducting joint research on cerebrospinal fluid biomarkers related to Alzheimer’s disease (AD). The two companies have agreed to move forward with their partnership based on the shared understanding that the development and commercialization of diagnostic methods for neurodegenerative diseases can be accelerated by integrating the long-standing respective expertise of Fujirebio, which has experience in the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom